In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]

Sreeranganathan M, Uthaman S, Sarmento B, et al. Int J Nanomedicine. 2017;12:7165–7182.   When reviewing the paper, the authors noted some errors in Figure 2E (page 7171) and Figure 6 (page 7176). They confirm that the corrections to Figures 2 and 6 do n...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Sreeranganathan M, Uthaman S, Sarmento B, Mohan CG, Park IK, Jayakumar R
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2019
Materias:
Acceso en línea:https://doaj.org/article/c2f4c508825840b29596534c2409cbb6
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c2f4c508825840b29596534c2409cbb6
record_format dspace
spelling oai:doaj.org-article:c2f4c508825840b29596534c2409cbb62021-12-02T06:40:28ZIn vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]1178-2013https://doaj.org/article/c2f4c508825840b29596534c2409cbb62019-06-01T00:00:00Zhttps://www.dovepress.com/corrigendum-in-vivo-evaluation-of-cetuximab-conjugated-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013Sreeranganathan M, Uthaman S, Sarmento B, et al. Int J Nanomedicine. 2017;12:7165–7182.   When reviewing the paper, the authors noted some errors in Figure 2E (page 7171) and Figure 6 (page 7176). They confirm that the corrections to Figures 2 and 6 do not alter the inferences or conclusion of the respective figures, nor the overall conclusion of the article, and apologize for this inadvertent error. In the original manuscript, Figure 2 represents the cellular internalization of the nanoparticles and Figure 2E represents the uptake of targeted nanoparticles by MKN-28 cells at a higher magnification. In Figure 2E, the fluorescence image was wrongly merged with the incorrect brightfield image of the cell. The authors have rectified this mistake by replacing Figure 2E with the confocal microscope image using the correct phase contrast, fluorescent, and merged images. The corrected version of Figure 2 is included as follows.   Read the original article  Sreeranganathan MUthaman SSarmento BMohan CGPark IKJayakumar RDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 14, Pp 4681-4682 (2019)
institution DOAJ
collection DOAJ
language EN
topic Medicine (General)
R5-920
spellingShingle Medicine (General)
R5-920
Sreeranganathan M
Uthaman S
Sarmento B
Mohan CG
Park IK
Jayakumar R
In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]
description Sreeranganathan M, Uthaman S, Sarmento B, et al. Int J Nanomedicine. 2017;12:7165–7182.   When reviewing the paper, the authors noted some errors in Figure 2E (page 7171) and Figure 6 (page 7176). They confirm that the corrections to Figures 2 and 6 do not alter the inferences or conclusion of the respective figures, nor the overall conclusion of the article, and apologize for this inadvertent error. In the original manuscript, Figure 2 represents the cellular internalization of the nanoparticles and Figure 2E represents the uptake of targeted nanoparticles by MKN-28 cells at a higher magnification. In Figure 2E, the fluorescence image was wrongly merged with the incorrect brightfield image of the cell. The authors have rectified this mistake by replacing Figure 2E with the confocal microscope image using the correct phase contrast, fluorescent, and merged images. The corrected version of Figure 2 is included as follows.   Read the original article  
format article
author Sreeranganathan M
Uthaman S
Sarmento B
Mohan CG
Park IK
Jayakumar R
author_facet Sreeranganathan M
Uthaman S
Sarmento B
Mohan CG
Park IK
Jayakumar R
author_sort Sreeranganathan M
title In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]
title_short In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]
title_full In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]
title_fullStr In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]
title_full_unstemmed In vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in EGFR-overexpressing gastric cancer xenografts [Corrigendum]
title_sort in vivo evaluation of cetuximab-conjugated poly(γ-glutamic acid)-docetaxel nanomedicines in egfr-overexpressing gastric cancer xenografts [corrigendum]
publisher Dove Medical Press
publishDate 2019
url https://doaj.org/article/c2f4c508825840b29596534c2409cbb6
work_keys_str_mv AT sreeranganathanm invivoevaluationofcetuximabconjugatedpolygammaglutamicaciddocetaxelnanomedicinesinegfroverexpressinggastriccancerxenograftscorrigendum
AT uthamans invivoevaluationofcetuximabconjugatedpolygammaglutamicaciddocetaxelnanomedicinesinegfroverexpressinggastriccancerxenograftscorrigendum
AT sarmentob invivoevaluationofcetuximabconjugatedpolygammaglutamicaciddocetaxelnanomedicinesinegfroverexpressinggastriccancerxenograftscorrigendum
AT mohancg invivoevaluationofcetuximabconjugatedpolygammaglutamicaciddocetaxelnanomedicinesinegfroverexpressinggastriccancerxenograftscorrigendum
AT parkik invivoevaluationofcetuximabconjugatedpolygammaglutamicaciddocetaxelnanomedicinesinegfroverexpressinggastriccancerxenograftscorrigendum
AT jayakumarr invivoevaluationofcetuximabconjugatedpolygammaglutamicaciddocetaxelnanomedicinesinegfroverexpressinggastriccancerxenograftscorrigendum
_version_ 1718399776999866368